Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.26
- Piotroski Score 3.00
- Grade Overweight
- Symbol (AUPH)
- Company Aurinia Pharmaceuticals Inc.
- Price $7.29
- Changes Percentage (1.82%)
- Change $0.13
- Day Low $7.11
- Day High $7.31
- Year High $10.05
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $12.00
- High Stock Price Target $13.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.43
- Trailing P/E Ratio -12.33
- Forward P/E Ratio -12.33
- P/E Growth -12.33
- Net Income $-78,020,000
Income Statement
Quarterly
Annual
Latest News of AUPH
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) most popular amongst retail investors who own 54% of the shares, institutions hold 35%
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has a diverse ownership structure, with retail investors holding the majority stake at 54%, followed by institutions at 35%. Hedge funds and insiders also ha...
By Yahoo! Finance | 3 months ago
